Bcal Diagnostics Ltd
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated… Read more
Bcal Diagnostics Ltd (BDX) - Net Assets
Latest net assets as of December 2025: AU$2.50 Million AUD
Based on the latest financial reports, Bcal Diagnostics Ltd (BDX) has net assets worth AU$2.50 Million AUD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$7.17 Million) and total liabilities (AU$4.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$2.50 Million |
| % of Total Assets | 34.82% |
| Annual Growth Rate | N/A |
| 5-Year Change | 72.47% |
| 10-Year Change | N/A |
| Growth Volatility | 267.67 |
Bcal Diagnostics Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Bcal Diagnostics Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bcal Diagnostics Ltd (2017–2024)
The table below shows the annual net assets of Bcal Diagnostics Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | AU$6.22 Million | -27.57% |
| 2023-12-31 | AU$8.59 Million | +64.73% |
| 2022-12-31 | AU$5.21 Million | -45.91% |
| 2021-12-31 | AU$9.64 Million | +167.26% |
| 2020-12-31 | AU$3.61 Million | +721.76% |
| 2019-12-31 | AU$438.92K | -10.09% |
| 2018-12-31 | AU$488.20K | +696.47% |
| 2017-12-31 | AU$-81.85K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bcal Diagnostics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2456489500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$33.83 Million | 543.89% |
| Other Comprehensive Income | AU$467.51K | 7.52% |
| Total Equity | AU$6.22 Million | 100.00% |
Bcal Diagnostics Ltd Competitors by Market Cap
The table below lists competitors of Bcal Diagnostics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jindo.Co. Ltd
KO:088790
|
$10.33 Million |
|
Minesto AB
ST:MINEST
|
$10.33 Million |
|
Proud Real Estate Public Company Limited
BK:PROUD
|
$10.33 Million |
|
APTAMER GROUP LTD LS-001
F:P0J
|
$10.34 Million |
|
Ryvyl Inc
NASDAQ:RVYL
|
$10.33 Million |
|
REMSleep Holdings Inc
OTCQB:RMSL
|
$10.32 Million |
|
Koroplast Temizlik Ambalaj Urunleri San. ve Dis Ticaret A.S.
IS:KRPLS
|
$10.32 Million |
|
Vinalink International Freight Forwarders
VN:VNL
|
$10.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bcal Diagnostics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,588,425 to 6,220,917, a change of -2,367,508 (-27.6%).
- Net loss of 7,241,035 reduced equity.
- Share repurchases of 115,007 reduced equity.
- New share issuances of 4,300,000 increased equity.
- Other comprehensive income decreased equity by 201,466.
- Other factors increased equity by 890,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-7.24 Million | -116.4% |
| Share Repurchases | AU$115.01K | -1.85% |
| Share Issuances | AU$4.30 Million | +69.12% |
| Other Comprehensive Income | AU$-201.47K | -3.24% |
| Other Changes | AU$890.00K | +14.31% |
| Total Change | AU$- | -27.57% |
Book Value vs Market Value Analysis
This analysis compares Bcal Diagnostics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | AU$0.00 | AU$0.09 | x |
| 2018-12-31 | AU$0.00 | AU$0.09 | x |
| 2019-12-31 | AU$0.00 | AU$0.09 | x |
| 2020-12-31 | AU$0.02 | AU$0.09 | x |
| 2021-12-31 | AU$0.05 | AU$0.09 | x |
| 2022-12-31 | AU$0.02 | AU$0.09 | x |
| 2023-12-31 | AU$0.03 | AU$0.09 | x |
| 2024-12-31 | AU$0.02 | AU$0.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bcal Diagnostics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -116.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33465.98%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.59x
- Recent ROE (-116.40%) is below the historical average (-76.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -193.01% | 0.43x | 0.00x | AU$-459.45K |
| 2018 | -88.07% | -166.49% | 0.48x | 1.11x | AU$-478.78K |
| 2019 | -158.65% | -157.51% | 0.54x | 1.87x | AU$-740.25K |
| 2020 | -42.28% | -554.03% | 0.07x | 1.15x | AU$-1.89 Million |
| 2021 | -35.12% | -471.08% | 0.07x | 1.10x | AU$-4.35 Million |
| 2022 | -97.08% | -181.39% | 0.33x | 1.61x | AU$-5.58 Million |
| 2023 | -74.52% | -206.58% | 0.25x | 1.43x | AU$-7.26 Million |
| 2024 | -116.40% | -33465.98% | 0.00x | 1.59x | AU$-7.86 Million |
Industry Comparison
This section compares Bcal Diagnostics Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $176,559,183
- Average return on equity (ROE) among peers: -18.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bcal Diagnostics Ltd (BDX) | AU$2.50 Million | 0.00% | 1.87x | $10.33 Million |
| Australian Clinical Labs Ltd (ACL) | $68.99 Million | 59.80% | 4.31x | $217.50 Million |
| Capitol Health Ltd (CAJ) | $144.04 Million | 0.60% | 0.82x | $222.66 Million |
| Cryosite Ltd (CTE) | $1.45 Million | 126.98% | 12.60x | $5.03 Million |
| Genetic Signatures Ltd (GSS) | $16.18 Million | -10.68% | 0.02x | $8.20 Million |
| Healius Ltd (HLS) | $1.04 Billion | -62.05% | 1.87x | $208.81 Million |
| Inoviq Ltd (IIQ) | $2.83 Million | -115.42% | 0.16x | $23.33 Million |
| Microba Life Sciences Ltd (MAP) | $32.49 Million | -45.98% | 0.46x | $10.42 Million |
| Monash Ivf Group Ltd (MVF) | $268.44 Million | 9.37% | 0.33x | $116.82 Million |
| Pacific Edge Ltd (PEB) | $13.91 Million | -128.81% | 0.19x | $89.67 Million |